Systemic therapies in advanced epithelioid ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.
Auteur(s) :
Frezza, A. M. [Auteur]
Ravi, V. [Auteur]
Lo Vullo, S. [Auteur]
Vincenzi, B. [Auteur]
Tolomeo, F. [Auteur]
Chen, T. W. [Auteur]
Teterycz, P. [Auteur]
Baldi, G. G. [Auteur]
Italiano, A. [Auteur]
Institut Bergonié [Bordeaux]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Brunello, A. [Auteur]
Duffaud, Florance [Auteur]
Aix Marseille Université [AMU]
Hindi, N. [Auteur]
Iwata, S. [Auteur]
Smrke, A. [Auteur]
Fedenko, A. [Auteur]
Gelderblom, H. [Auteur]
Van Der Graaf, W. [Auteur]
Vozy, A. [Auteur]
Connolly, E. [Auteur]
Grassi, M. [Auteur]
Benjamin, R. S. [Auteur]
Broto, J. M. [Auteur]
Grignani, G. [Auteur]
Jones, R. L. [Auteur]
Kawai, A. [Auteur]
Tysarowski, A. [Auteur]
Mariani, L. [Auteur]
Casali, P. G. [Auteur]
Stacchiotti, S. [Auteur]
Ravi, V. [Auteur]
Lo Vullo, S. [Auteur]
Vincenzi, B. [Auteur]
Tolomeo, F. [Auteur]
Chen, T. W. [Auteur]
Teterycz, P. [Auteur]
Baldi, G. G. [Auteur]
Italiano, A. [Auteur]
Institut Bergonié [Bordeaux]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Brunello, A. [Auteur]
Duffaud, Florance [Auteur]
Aix Marseille Université [AMU]
Hindi, N. [Auteur]
Iwata, S. [Auteur]
Smrke, A. [Auteur]
Fedenko, A. [Auteur]
Gelderblom, H. [Auteur]
Van Der Graaf, W. [Auteur]
Vozy, A. [Auteur]
Connolly, E. [Auteur]
Grassi, M. [Auteur]
Benjamin, R. S. [Auteur]
Broto, J. M. [Auteur]
Grignani, G. [Auteur]
Jones, R. L. [Auteur]
Kawai, A. [Auteur]
Tysarowski, A. [Auteur]
Mariani, L. [Auteur]
Casali, P. G. [Auteur]
Stacchiotti, S. [Auteur]
Titre de la revue :
Cancer Medicine
Date de publication :
2021-03-21
ISSN :
2045-7634
Mot(s)-clé(s) :
anthracycline
chemotherapy
epithelioid haemangioendothelioma
interferon
paclitaxel
pazopanib
chemotherapy
epithelioid haemangioendothelioma
interferon
paclitaxel
pazopanib
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background
This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra-rare sarcoma, marked by WWTR1-CAMTA1 or YAP1-TFE3 fusions.
...
Lire la suite >Background This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra-rare sarcoma, marked by WWTR1-CAMTA1 or YAP1-TFE3 fusions. Methods Twenty sarcoma reference centres contributed data. Patients with advanced EHE diagnosed from 2000 onwards and treated with systemic therapies, were selected. Local pathologic review and molecular confirmation were required. Radiological response was retrospectively assessed by local investigators according to RECIST. Progression free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method. Results Overall, 73 patients were included; 21 had more than one treatment. Thirty-three patients received anthracyclines regimens, achieving 1 (3%) partial response (PR), 25 (76%) stable disease (SD), 7 (21%) progressive disease (PD). The median (m-) PFS and m-OS were 5.5 and 14.3 months respectively. Eleven patients received paclitaxel, achieving 1 (9%) PR, 6 (55%) SD, 4 (36%) PD. The m-PFS and m-OS were 2.9 and 18.6 months, respectively. Twelve patients received pazopanib, achieving 3 (25%) SD, 9 (75%) PD. The m-PFS and m-OS were.2.9 and 8.5 months, respectively. Fifteen patients received INF-α 2b, achieving 1 (7%) PR, 11 (73%) SD, 3 (20%) PD. The m-PFS and m-OS were 8.9 months and 64.3, respectively. Among 27 patients treated with other regimens, 1 PR (ifosfamide) and 9 SD (5 gemcitabine +docetaxel, 2 oral cyclophosphamide, 2 others) were reported. Conclusion Systemic therapies available for advanced sarcomas have limited activity in EHE. The identification of new active compounds, especially for rapidly progressive cases, is acutely needed.Lire moins >
Lire la suite >Background This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra-rare sarcoma, marked by WWTR1-CAMTA1 or YAP1-TFE3 fusions. Methods Twenty sarcoma reference centres contributed data. Patients with advanced EHE diagnosed from 2000 onwards and treated with systemic therapies, were selected. Local pathologic review and molecular confirmation were required. Radiological response was retrospectively assessed by local investigators according to RECIST. Progression free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method. Results Overall, 73 patients were included; 21 had more than one treatment. Thirty-three patients received anthracyclines regimens, achieving 1 (3%) partial response (PR), 25 (76%) stable disease (SD), 7 (21%) progressive disease (PD). The median (m-) PFS and m-OS were 5.5 and 14.3 months respectively. Eleven patients received paclitaxel, achieving 1 (9%) PR, 6 (55%) SD, 4 (36%) PD. The m-PFS and m-OS were 2.9 and 18.6 months, respectively. Twelve patients received pazopanib, achieving 3 (25%) SD, 9 (75%) PD. The m-PFS and m-OS were.2.9 and 8.5 months, respectively. Fifteen patients received INF-α 2b, achieving 1 (7%) PR, 11 (73%) SD, 3 (20%) PD. The m-PFS and m-OS were 8.9 months and 64.3, respectively. Among 27 patients treated with other regimens, 1 PR (ifosfamide) and 9 SD (5 gemcitabine +docetaxel, 2 oral cyclophosphamide, 2 others) were reported. Conclusion Systemic therapies available for advanced sarcomas have limited activity in EHE. The identification of new active compounds, especially for rapidly progressive cases, is acutely needed.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Date de dépôt :
2023-11-15T07:05:44Z
2023-11-24T12:53:44Z
2023-11-24T12:53:44Z
Fichiers
- Cancer Medicine - 2021 - Frezza - Systemic therapies in advanced epithelioid haemangioendothelioma A retrospective.pdf
- Version éditeur
- Accès libre
- Accéder au document